Drug Profile
Research programme: antibodies - Biolingus
Alternative Names: Project B1 (SEED) - BiolingusLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Biolingus
- Class Anti-inflammatories; Antibodies; Biobetters; Skin disorder therapies
- Mechanism of Action Immunomodulators; Interleukin 23 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Crohn's disease; Psoriasis
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Crohn's-disease in Switzerland (Sublingual)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Psoriasis in Switzerland (Sublingual)
- 18 Sep 2017 The antibodies are available for licensing as of 18 Sep 2017. http://www.biolingus.ch/index.html#partners